| Number | RR | 95% CI lower limit | 95% CI upper limit | P-value | Overall p value |
---|---|---|---|---|---|---|
Chronic GVHD | ||||||
 ATG/alemtuzumab | ||||||
  No | 174 | 1 |  |  |  | 0.02 |
  Yes | 55 | 0.58 | 0.36 | 0.93 | 0.02 |  |
Progression/Relapse | ||||||
 No significant covariates | ||||||
Non-relapse mortality | ||||||
 No significant covariates | ||||||
Progression-free survival | ||||||
 Disease status | ||||||
  CR | 108 | 1 |  |  |  | 0.03 |
  PR | 90 | 1.13 | 0.76 | 1.66 | 0.54 |  |
  Chemoresistant | 38 | 1.73 | 1.08 | 2.77 | 0.02 |  |
  Missing/Untreated | 13 | 0.43 | 0.15 | 1.20 | 0.11 |  |
Overall survival | ||||||
 Karnofsky performance score (≤ 6 months)a | ||||||
  ≥ 90% | 119 | 1 |  |  |  | 0.002 |
  < 90% | 113 | 3.46 | 1.74 | 6.87 | 0.0004 |  |
  Missing | 17 | 1.95 | 0.54 | 6.98 | 0.31 |  |
 Karnofsky performance score (> 6 months)a | ||||||
  ≥ 90% | 106 | 1 |  |  |  | 0.28 |
  < 90% | 80 | 0.66 | 0.39 | 1.12 | 0.12 |  |
  Missing | 14 | 0.73 | 0.29 | 1.86 | 0.51 |  |